Business · 09/07/2024

FDA Releases Draft Guidance on Use-Related Risk Analyses for Drugs and Biologics

The Food and Drug Administration (FDA) has released a draft guidance document titled 'Purpose and Content of Use-Related Risk Analyses for Drugs, Biological Products, and Combination Products' to provide industry and FDA staff with information on use-related risk analyses and their application in product development and marketing applications.